Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Saitama Cancer Center, Saitama, Japan

2 abstracts

Abstract
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.
Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,
Abstract
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).
Org: The Ohio State University Comprehensive Cancer Center, Columbus, OH, Institutul Oncologic Prof Dr Ion Chiricută and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, SF Nectarie Oncology Center, Craiova, Romania, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, L’institut du Thorax, Nantes, France,